Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation

Br J Haematol. 2003 Nov;123(4):746-7. doi: 10.1046/j.1365-2141.2003.04675.x.
No abstract available

Publication types

  • Clinical Trial
  • Comment
  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Combined Modality Therapy
  • Disease-Free Survival
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / mortality
  • Multiple Myeloma / therapy
  • Peripheral Blood Stem Cell Transplantation
  • Rituximab
  • Treatment Failure

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab